HK1093522A1 - A process for the purification or production of a mage protein - Google Patents

A process for the purification or production of a mage protein

Info

Publication number
HK1093522A1
HK1093522A1 HK06111055.3A HK06111055A HK1093522A1 HK 1093522 A1 HK1093522 A1 HK 1093522A1 HK 06111055 A HK06111055 A HK 06111055A HK 1093522 A1 HK1093522 A1 HK 1093522A1
Authority
HK
Hong Kong
Prior art keywords
purification
production
mage protein
mage
protein
Prior art date
Application number
HK06111055.3A
Other languages
English (en)
Inventor
Silva Teresa Cabezon
Joseph Cohen
Moncef Mohamed Slaoui
Bassols Carlota Vinals
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802543.0A external-priority patent/GB9802543D0/en
Priority claimed from GBGB9802650.3A external-priority patent/GB9802650D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of HK1093522A1 publication Critical patent/HK1093522A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK06111055.3A 1998-02-05 2001-05-11 A process for the purification or production of a mage protein HK1093522A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine
GBGB9802650.3A GB9802650D0 (en) 1998-02-06 1998-02-06 Vaccine
HK06101448.0A HK1083026A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination

Publications (1)

Publication Number Publication Date
HK1093522A1 true HK1093522A1 (en) 2007-03-02

Family

ID=26313069

Family Applications (4)

Application Number Title Priority Date Filing Date
HK01103307A HK1033838A1 (en) 1998-02-05 2001-05-11 Tumor-asociated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and ofcompositions for vaccination
HK06101448.0A HK1083026A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination
HK06111055.3A HK1093522A1 (en) 1998-02-05 2001-05-11 A process for the purification or production of a mage protein
HK06111054.4A HK1093521A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK01103307A HK1033838A1 (en) 1998-02-05 2001-05-11 Tumor-asociated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and ofcompositions for vaccination
HK06101448.0A HK1083026A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK06111054.4A HK1093521A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination

Country Status (26)

Country Link
US (3) US8097257B2 (hu)
EP (4) EP1053325B1 (hu)
JP (2) JP4768121B2 (hu)
KR (2) KR100633212B1 (hu)
CN (1) CN1227360C (hu)
AR (1) AR018064A1 (hu)
AT (4) ATE315088T1 (hu)
AU (1) AU737337B2 (hu)
BR (1) BR9907691B1 (hu)
CA (2) CA2319309C (hu)
CY (4) CY1105685T1 (hu)
CZ (2) CZ298364B6 (hu)
DE (3) DE69942214D1 (hu)
DK (4) DK1659178T3 (hu)
ES (2) ES2255248T3 (hu)
HK (4) HK1033838A1 (hu)
HU (1) HU228467B1 (hu)
IL (4) IL137442A0 (hu)
NO (2) NO328507B1 (hu)
NZ (1) NZ506086A (hu)
PT (4) PT1659179E (hu)
SA (1) SA99200126B1 (hu)
SI (4) SI1659179T1 (hu)
TR (1) TR200002284T2 (hu)
TW (1) TWI238853B (hu)
WO (1) WO1999040188A2 (hu)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228467B1 (en) 1998-02-05 2013-03-28 Smithkline Beecham Biolog Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
US7005498B1 (en) 1998-10-05 2006-02-28 Pharmexa A/S Methods for therapeutic vaccination
EP1502602A3 (en) * 1998-10-05 2006-05-17 Pharmexa A/S Methods for therapeutic vaccination
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
CA2400842C (en) * 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Novel compounds
EP1385541B1 (en) * 2000-04-13 2008-06-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
EP3333182A1 (en) * 2000-06-05 2018-06-13 The Brigham and Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
AU6867801A (en) 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
PL211151B1 (pl) 2000-10-18 2012-04-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
PL208755B1 (pl) * 2000-10-18 2011-06-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2003050268A2 (en) 2001-12-12 2003-06-19 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
US7534585B2 (en) 2003-07-21 2009-05-19 Transgene S.A. Multifunctional cytokines
US20060257880A1 (en) * 2003-08-29 2006-11-16 The Nottingham Trent University Gastric and prostate cancer associated antigens
EP2481422A3 (en) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
CN101184504A (zh) 2005-03-31 2008-05-21 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
CA2821389C (en) 2005-04-29 2015-11-17 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating m tuberculosis infection
AU2006251098B2 (en) * 2005-05-26 2011-09-15 Kuros Us Llc Scalable fermentation process
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1951891B1 (en) * 2005-11-14 2012-02-15 Université Laval Cancer antigen mage-a9 and uses thereof
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5170976B2 (ja) * 2006-04-11 2013-03-27 株式会社イミュノフロンティア タンパク質複合体およびその製造方法
EP2390353A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the CD69 gene.
GB0612342D0 (en) 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE037808T2 (hu) 2006-09-26 2018-09-28 Infectious Disease Res Inst Szintetikus adalékanyagot tartalmazó vakcina kompozíció
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
MX2009007571A (es) * 2007-01-15 2009-07-22 Glaxosmithkline Biolog Sa Vacuna.
WO2009039986A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent
RU2010114017A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Терапевтическое применение натрийуретического пептида в-типа и гормона роста человека 1-43
MX2010002965A (es) 2007-09-17 2010-09-14 Oncomethylome Sciences Sa Deteccion mejorada de la expresion de mage-a.
EP2200642B1 (en) * 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
AU2010225125A1 (en) 2009-03-17 2011-10-20 Glaxosmithkline Biologicals S.A. Improved detection of gene expression
KR20120014054A (ko) 2009-05-27 2012-02-15 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃａｓｂ7439 작제물
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
MX2012008790A (es) 2010-01-27 2012-08-17 Glaxosmithkline Biolog Sa Antigenos de tuberculosis modificados.
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2014510721A (ja) 2011-02-15 2014-05-01 イミューン デザイン コーポレイション ベクターワクチンによる免疫原特異的免疫応答を強化するための方法
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
CN102251034B (zh) * 2011-07-05 2012-11-21 北京大学人民医院 基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
ES2702495T3 (es) 2011-08-30 2019-03-01 Astex Pharmaceuticals Inc Formulaciones de derivados de decitabina
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
JP2015503503A (ja) * 2011-12-22 2015-02-02 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Ｂｒａｆ阻害剤および／またはｍｅｋ阻害剤とともにｍａｇｅａ３免疫療法薬を用いた癌の治療方法
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
CN104870477B (zh) 2012-10-23 2018-10-09 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
HUE044430T2 (hu) 2013-03-01 2019-10-28 Astex Pharmaceuticals Inc Gyógyszerkombinációk
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
EP3542816A1 (en) 2014-02-14 2019-09-25 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
BR112018000054A2 (pt) 2015-07-02 2018-09-04 Otsuka Pharmaceutical Co., Ltd. composições farmacêuticas liofilizadas
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途
KR102566134B1 (ko) 2015-12-07 2023-08-10 삼성전자주식회사 반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
CA3020542A1 (en) 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
US11344619B2 (en) 2016-05-16 2022-05-31 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
KR20200028395A (ko) 2017-06-15 2020-03-16 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
WO2020106621A1 (en) 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
US20220031749A1 (en) 2018-11-28 2022-02-03 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
BR112021010248A2 (pt) 2018-11-29 2021-08-17 Board Of Regents, The University Of Texas System métodos para expansão ex vivo de células naturais killer e uso dos mesmos
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
CA3173951A1 (en) 2020-09-04 2022-03-10 Emily VOIGT Genetically-adjuvanted rna vaccines
AU2021377699A1 (en) 2020-11-13 2023-06-15 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CN117120087A (zh) 2020-12-23 2023-11-24 高级健康研究所 茄尼醇疫苗助剂及其制备方法
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AR241713A1 (es) 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ZA896627B (en) * 1988-08-31 1991-03-27 Smithkline Beecham Corp Vaccinal polypeptides
GB8824496D0 (en) 1988-10-19 1988-11-23 Beecham Group Plc Process
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
CA2022752C (en) 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE107665T1 (de) 1990-07-23 1994-07-15 Zymogenetics Inc Proteaseresistenter pdgf und dessen verwendungen.
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5925729A (en) 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
WO1993009806A1 (en) 1991-11-14 1993-05-27 Brigham And Women's Hospital Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
DK0761231T3 (da) 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
GB9213559D0 (en) 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
CA2143335C (en) 1992-08-31 2000-03-14 Thierry Boon-Falleur Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
NZ271774A (en) * 1993-08-06 1998-02-26 Cytel Corp Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0871765B1 (en) 1994-03-01 2001-11-28 Ludwig Institute For Cancer Research Determination of cancerous conditions by mage gene expression
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AU690371B2 (en) * 1994-09-30 1998-04-23 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0873350A4 (en) 1995-06-29 1999-06-30 Ludwig Inst Cancer Res ISOLATION OF A NUCLEIC ACID MOLECULE ENCODING SMAGE-3, A MURINE TUMOR REJECTION ANTIGEN PRECURSOR
AU7440196A (en) 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
CA2218456A1 (en) 1996-10-15 1998-04-15 The Rockefeller University Purified stat proteins and methods of purifying thereof
WO1998020165A2 (en) 1996-11-06 1998-05-14 Whitehead Institute For Biomedical Research Biallelic markers
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
US6027924A (en) 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US20020176865A1 (en) 1997-04-25 2002-11-28 Sophie Lucas Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
HU228467B1 (en) 1998-02-05 2013-03-28 Smithkline Beecham Biolog Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
WO1999053095A2 (en) 1998-04-09 1999-10-21 Whitehead Institute For Biomedical Research Biallelic markers
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor

Also Published As

Publication number Publication date
CN1295616A (zh) 2001-05-16
BR9907691A (pt) 2000-11-14
DK1053325T3 (da) 2006-05-22
ATE513042T1 (de) 2011-07-15
CY1111831T1 (el) 2015-10-07
SI1053325T1 (sl) 2006-06-30
HU228467B1 (en) 2013-03-28
PT1659179E (pt) 2011-09-16
NO20003958L (no) 2000-10-04
HK1033838A1 (en) 2001-09-28
IL188875A0 (en) 2009-02-11
ATE505542T1 (de) 2011-04-15
NO20003958D0 (no) 2000-08-04
NO331719B1 (no) 2012-03-05
CZ298364B6 (cs) 2007-09-05
DE69943359D1 (de) 2011-05-26
ES2255248T3 (es) 2006-06-16
PT1659178E (pt) 2010-06-28
JP2009201510A (ja) 2009-09-10
WO1999040188A2 (en) 1999-08-12
US20100204458A1 (en) 2010-08-12
HUP0102639A3 (en) 2004-04-28
NO328507B1 (no) 2010-03-08
US8044183B2 (en) 2011-10-25
WO1999040188A3 (en) 1999-10-14
CY1105685T1 (el) 2010-12-22
KR20010040675A (ko) 2001-05-15
AU737337B2 (en) 2001-08-16
EP1659178A3 (en) 2007-01-17
NZ506086A (en) 2003-01-31
DK1659178T3 (da) 2010-07-12
EP1053325B1 (en) 2006-01-04
ES2342416T3 (es) 2010-07-06
CY1110180T1 (el) 2015-01-14
PL342852A1 (en) 2001-07-16
IL188875A (en) 2011-08-31
EP1659179A2 (en) 2006-05-24
CA2584482C (en) 2012-03-27
IL137442A0 (en) 2001-07-24
AR018064A1 (es) 2001-10-31
US20120269835A1 (en) 2012-10-25
EP1659179A3 (en) 2007-01-17
KR20060067977A (ko) 2006-06-20
JP4768121B2 (ja) 2011-09-07
HK1083026A1 (en) 2006-06-23
AU2722099A (en) 1999-08-23
PT1584685E (pt) 2011-06-17
DE69929310D1 (de) 2006-03-30
US8097257B2 (en) 2012-01-17
HUP0102639A1 (hu) 2001-11-28
CZ298347B6 (cs) 2007-09-05
DE69942214D1 (de) 2010-05-12
CA2319309A1 (en) 1999-08-12
EP1584685A3 (en) 2005-12-07
DE69929310T2 (de) 2006-08-03
TWI238853B (en) 2005-09-01
CY1111672T1 (el) 2015-10-07
ATE315088T1 (de) 2006-02-15
ATE462788T1 (de) 2010-04-15
KR100633212B1 (ko) 2006-10-11
DK1659179T3 (da) 2011-10-10
SI1584685T1 (sl) 2011-07-29
BR9907691B1 (pt) 2011-05-31
EP1659178A2 (en) 2006-05-24
IL137442A (en) 2008-04-13
US20100209444A1 (en) 2010-08-19
DK1584685T3 (da) 2011-07-11
SI1659178T1 (sl) 2010-07-30
CA2319309C (en) 2010-08-10
HK1093521A1 (en) 2007-03-02
EP1659179B1 (en) 2011-06-15
CN1227360C (zh) 2005-11-16
PT1053325E (pt) 2006-05-31
CA2584482A1 (en) 1999-08-12
EP1659178B1 (en) 2010-03-31
SA99200126B1 (ar) 2006-08-20
JP2002502604A (ja) 2002-01-29
US8597656B2 (en) 2013-12-03
EP1584685A2 (en) 2005-10-12
EP1053325A2 (en) 2000-11-22
CZ20002869A3 (cs) 2001-01-17
NO20091665L (no) 2000-10-04
IL179010A0 (en) 2007-03-08
TR200002284T2 (tr) 2000-11-21
EP1584685B1 (en) 2011-04-13
KR100824105B1 (ko) 2008-04-21
SI1659179T1 (sl) 2011-10-28

Similar Documents

Publication Publication Date Title
HK1093522A1 (en) A process for the purification or production of a mage protein
IL124800A0 (en) Process for the production of vanillin
HUP0103946A3 (en) Process for the production of olefins
EG22451A (en) Purification process
GB9908550D0 (en) Process for the purification of brines
SG65049A1 (en) Process for the production of polyther polyols
IL133363A (en) Process for the production of herapin
ZA9811382B (en) Process for the production of N-propanol.
HK1040950A1 (en) Purification process for chromium
ZA98898B (en) Process for the production of halogeno-o-hydroxydiphenyl compounds
PL341712A1 (en) Tramadole purification process
GB2323843B (en) Method for the production of alkoxy-and arloxy-phenols
IL124178A (en) Process for the production of distryryl-biphenyl compounds
GB9800657D0 (en) Improved purification process
SG78300A1 (en) Production process
IL149713A0 (en) Process for the production of trifluormethylacetophenones
IL131765A0 (en) Process for the purification of substituted p-nitrodiphenylethers
HUP0004950A3 (en) Process for the production of formylimidazoles
GB9821822D0 (en) Process for the manufacture of a product
HK1020438A1 (en) Process for the production of 2h-1-benzopyrans
IL125541A0 (en) Process for the production of 5-hydroxyoxazolidinones
IL140549A0 (en) A process for the production of fibrous protein
ZA977562B (en) Process for the production of 2H-1-benzopyrans
SI0882035T1 (en) Process for the production of 2h-1-benzopyrans
GB9617673D0 (en) Process for the production of mono-olefins

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150202